Shots:Shots: The Phase 1/2 study assesses the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion of […]readmore
Tags : P-I/II
Shots: The companies reported that the first cohort of BioNTech’s P-I/II clinical trial has dosed 12 participants with BNT162 in Germany since dosing began on Apr 23, 2020. Following the […]readmore
Shots: The P-I/II study will assess the safety & efficacy of AGN-151587 (subretinal injection) in ~18 patients with Leber congenital amaurosis 10. The patients enrolled are both adult & pediatric […]readmore
Shots: The partial hold on clinical study for intrathecal administration of AVXS-101 follows the findings of the pre-clinical study demonstrated dorsal root ganglia (DRG) mononuclear cell inflammation accompanied by neuronal […]readmore
Shots: The P-I/II STRONG study involves assessing AVXS-101 (IT) in patients with SMA Type 2 who have three copies of the SMN2 gene, and who can sit but cannot stand […]readmore
Shots: The Multiple Studies P-III ECHELON-1 (Adcetris + CT vs CT), P-I/II & P-II (Adcetris + Opdivo(nivolumab)) and P-III AETHERA (Adcetris) is evaluated in patients with stage III or IV […]readmore